Advice
in the absence of a submission from the holder of the marketing authorisation:
pembrolizumab (Keytruda®) is not recommended for use within NHSScotland.
Indication under review: in combination with gemcitabine and cisplatin for the first-line treatment of locally advanced unresectable or metastatic biliary tract carcinoma in adults.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice237KB (PDF)
Medicine details
- Medicine name:
- pembrolizumab (Keytruda)
- SMC ID:
- SMC2683
- Indication:
In combination with gemcitabine and cisplatin for the first-line treatment of locally advanced unresectable or metastatic biliary tract carcinoma in adults.
- Pharmaceutical company
- Merck Sharp & Dohme Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 10 June 2024